May 15 2012
To reduce radiation dose while maintaining high image quality, Steinberg
Diagnostic Medical Imaging Center (SDMI) in Las Vegas has installed the
first AquilionTM PRIME 160 series from Toshiba America
Medical Systems, Inc. in the U.S. Reinforcing the principle of As Low As
Reasonably Achievable (ALARA), SDMI uses Adaptive Iterative Dose
Reduction (AIDR) and NEMA XR 25 Dose Check Software to conduct a variety
of general imaging exams while minimizing radiation dose. SDMI will soon
be upgraded to Toshiba's recently FDA-cleared AIDR 3D software to
further enhance dose reduction and image quality.
"With dose-reduction features such as AIDR, active collimation and dose
modulation, the system can make adjustments in real time to reduce
radiation exposure while maintaining the image quality needed for
diagnoses," said Dr. Mark Winkler, professor of health sciences at the
University of Nevada, Las Vegas, and founding partner of SDMI.
"Additionally, the wide, open bore and high-speed rotation make exams
more comfortable and quicker for any patient type."
The Aquilion PRIME can generate 160 unique slices per rotation and
features a 7.5-MHU large-capacity tube and 0.35-second scanning. This
high-speed rotation allows rapid data acquisition and shortens scan
times while the fast reconstruction unit further improves throughput,
reducing time required for diagnoses. The system also features a 78-cm
aperture gantry, the largest currently available in a high-end CT
system. The combination of a 660-pound patient-weight-capacity couch
with a large gantry bore makes the Aquilion PRIME an ideal system for
use in emergency scanning or bariatric patient studies.
"Aquilion PRIME was designed for healthcare facilities that need to
perform a wide variety of advanced clinical examinations and produce
high-quality clinical images with reduced radiation exposure," said Tim
Nicholson, senior manager, Market Development, CT Business Unit,
Toshiba. "With Aquilion PRIME, SDMI can conduct many general imaging
exams and many advanced applications, like low-dose prospective cardiac
CTA."
Source:
Toshiba America Medical Systems, Inc.